无创通气患者潮气量的评估:系统评价与荟萃分析
该系统评价与荟萃分析纳入11项观察性研究共1136例接受NIV的成人急性呼吸衰竭患者,比较NIV成功与失败组的潮气量。结果显示失败组Vt/PBW更高(MD 1.02 mL/kg,95%CI 0.60-1.45),绝对Vt无差异;低氧性ARF中失败组Vt/PBW仍更高(MD 0.89 mL/kg,95%CI 0.04-1.73),高碳酸血症性ARF无数据。事后分析显示较高Vt/PBW与死亡率增加(OR 9.11,95%CI 3.88-21.37)、呼吸频率更高(MD 3.14次/分,95%CI 1.36-4.92)及Paco2更低(MD -2.38 mmHg,95%CI -4.16至-0.5938)相关,但与压力支持水平无关。证据确定性为极低至中等,反映预后关联而非因果。
要点
- 成人ARF接受NIV时,NIV失败组Vt/PBW较成功组高1.02 mL/kg(95%CI 0.60-1.45),绝对Vt无差异。
- 低氧性ARF亚组中,NIV失败组Vt/PBW仍更高(MD 0.89 mL/kg,95%CI 0.04-1.73);高碳酸血症性ARF无可用数据。
- 事后分析:较高Vt/PBW与死亡率增加相关(OR 9.11,95%CI 3.88-21.37),并伴呼吸频率更高(MD 3.14次/分)和Paco2更低(MD -2.38 mmHg)。
- 较高Vt/PBW与压力支持水平无关(MD 0.24,95%CI -0.81至1.29),结合RR升高和Paco2降低提示呼吸驱动增高是死亡驱动因素。
- 证据确定性极低至中等,为预后关联而非因果关系,需系统监测Vt的干预性研究验证。
适用人群与场景
- 成人急性呼吸衰竭接受无创通气治疗的患者,纳入观察性研究,报告NIV成功与失败组的潮气量或Vt/PBW。
- 低氧性ARF亚组有数据;高碳酸血症性ARF无可用数据。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 系统评价与荟萃分析纳入11项观察性研究共1136例成人ARF接受NIV的患者。
- NIV失败组Vt/PBW高于成功组(MD 1.02 mL/kg,95%CI 0.60-1.45 mL/kg),绝对Vt无差异(MD 1.30,95%CI -33.31至35.91)。
- 低氧性ARF中NIV失败组Vt/PBW更高(MD 0.89 mL/kg,95%CI 0.04-1.73 mL/kg);高碳酸血症性ARF无数据。
- 事后分析:较高Vt/PBW与死亡率增加(OR 9.11,95%CI 3.88-21.37)、呼吸频率更高(MD 3.14次/分,95%CI 1.36-4.92)和Paco2更低(MD -2.38 mmHg,95%CI -4.16至-0.5938)相关,与压力支持水平无关(MD 0.24,95%CI -0.81至1.29)。
- 证据确定性范围为极低至中等。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入观察性研究。
- 使用ROBINS-I评估偏倚风险,GRADE评估证据确定性,确定性范围为极低至中等。
- 局限:仅观察性研究,反映预后关联而非因果关系;高碳酸血症性ARF无数据;需干预性研究验证。
对床旁实践的改变
- 在成人ARF无创通气中,应关注Vt/PBW而非绝对Vt,较高Vt/PBW提示NIV失败和死亡风险增加,尤其低氧性ARF。
- 较高Vt/PBW伴呼吸频率增高和Paco2降低提示呼吸驱动增高,可能需干预降低驱动,但原文未给出具体干预措施。
- 证据为预后关联,不能据此确定Vt/PBW治疗阈值;需前瞻性干预研究验证系统监测Vt的价值。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Noninvasive ventilation (NIV) is widely used in acute respiratory failure (ARF), yet the association between high tidal volume (Vt) and clinical outcomes remains incompletely defined. We evaluated the association between Vt and NIV failure overall and by ARF type, and its relationship with respiratory and clinical outcomes.
DATA SOURCES: MEDLINE, Cochrane Central Register of Controlled Trials, Web of Science, and Latin American and Caribbean Health Science Literature (1976 to September 2025).
STUDY SELECTION: Observational studies of adults with ARF treated with NIV reporting Vt or Vt normalized to predicted body weight (Vt/PBW) in NIV success and failure groups.
DATA EXTRACTION: Three pairs of reviewers identified studies and extracted data independently. Random-effects meta-analysis was performed. Risk of bias and certainty of evidence were assessed using Risk of Bias In Nonrandomized Studies of Interventions and Grading of Recommendations Assessment, Development, and Evaluation.
DATA SYNTHESIS: Eleven studies (1136 patients) were included. Vt/PBW was higher in NIV failure vs. success (mean difference [MD], 1.02 mL/kg [95% CI, 0.60-1.45 mL/kg]), whereas absolute Vt did not differ (MD, 1.30 [-33.31 to 35.91]). In hypoxemic ARF, Vt/PBW remained higher in NIV failure (MD, 0.89 mL/kg [95% CI, 0.04-1.73 mL/kg]); no data were available for hypercapnic ARF. Post hoc analyses showed that higher Vt/PBW was associated with increased mortality (odds ratio, 9.11; 95% CI, 3.88-21.37), higher respiratory rate (RR; MD, 3.14 breaths/min [95% CI, 1.36-4.92 breaths/min]), and lower Paco2 (MD, -2.38 mm Hg [95% CI, -4.16 to -0.5938 mm Hg]), but no with pressure support (PS) level (MD, 0.24 [95% CI, -0.81 to 1.29]). Certainty of evidence ranged from very low to moderate.
CONCLUSIONS: In adults with ARF treated with NIV, higher Vt/PBW was associated with NIV failure and worse outcomes. These findings reflect prognostic associations rather than causality, and interventional studies with systematic Vt monitoring are needed. Importantly, elevated Vt/PBW, higher RR, lower Paco2, and increased mortality, without differences in PS, collectively implicate elevated respiratory drive as a driver of increased mortality (PROSPERO [CRD42024584977]).Findings: Higher Vt/PBW was associated with NIV failure, particularly in hypoxemic respiratory failure; post hoc analyses showed associations with increased mortality, higher respiratory rate, and lower Paco2.
参考来源
- Santa Cruz R, Matesa A, Jara M, et al. Assessment of Tidal Volume in Patients Undergoing Noninvasive Ventilation: Systematic Review and Meta-Analysis. Crit Care Med. 2026. PMID: 42900697. doi:10.1097/CCM.0000000000007387
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。